Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.

IF 6.6 2区 医学 Q1 RESPIRATORY SYSTEM Respirology Pub Date : 2024-10-24 DOI:10.1111/resp.14843
Hendrik Pott, Barbara Weckler, Swetlana Gaffron, Roman Martin, Dieter Maier, Peter Alter, Frank Biertz, Tim Speicher, Wilhelm Bertrams, Anna Lena Jung, Katrin Laakmann, Dominik Heider, Miel Wouters, Claus F Vogelmeier, Bernd Schmeck
{"title":"Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.","authors":"Hendrik Pott, Barbara Weckler, Swetlana Gaffron, Roman Martin, Dieter Maier, Peter Alter, Frank Biertz, Tim Speicher, Wilhelm Bertrams, Anna Lena Jung, Katrin Laakmann, Dominik Heider, Miel Wouters, Claus F Vogelmeier, Bernd Schmeck","doi":"10.1111/resp.14843","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV<sub>1</sub>, SGRQ, exacerbation history) and associated with unique baseline biomarker profiles. We explored 18-month measures of disease progression associated with 18-54-month mortality, including changes in hyperinflation parameters and transfer factor, in a large German COPD cohort.</p><p><strong>Methods: </strong>Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models.</p><p><strong>Results: </strong>Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV<sub>1</sub> (20 mL increments), increase in RV/TLC (2% increments) and SGRQ (≥6 points), and an exacerbation grade of 2 at 18 months. Decrease in KCO % predicted ≥7.5% and an increase of RV/TLC ≥2% were the most frequent measures of 18-month disease progression occurring in ~52% and ~46% of patients, respectively. IL-6 and CRP thresholds exhibited significant associations with medium- and long-term disease measures.</p><p><strong>Conclusion: </strong>In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.14843","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV1, SGRQ, exacerbation history) and associated with unique baseline biomarker profiles. We explored 18-month measures of disease progression associated with 18-54-month mortality, including changes in hyperinflation parameters and transfer factor, in a large German COPD cohort.

Methods: Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models.

Results: Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV1 (20 mL increments), increase in RV/TLC (2% increments) and SGRQ (≥6 points), and an exacerbation grade of 2 at 18 months. Decrease in KCO % predicted ≥7.5% and an increase of RV/TLC ≥2% were the most frequent measures of 18-month disease progression occurring in ~52% and ~46% of patients, respectively. IL-6 and CRP thresholds exhibited significant associations with medium- and long-term disease measures.

Conclusion: In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为疾病进展标志物的扩散能力和静态过度充气可预测慢性阻塞性肺病的 3 年死亡率:COSYCONET 的研究结果。
背景和目的:慢性阻塞性肺病(COPD)因其潜在的疾病活动而表现出不同的疾病进展模式。我们假设,静态过度充气或 KCO % 预测值的变化将揭示疾病进展亚组,这些亚组无法通过预先确定的标志物(FEV1、SGRQ、恶化史)识别,并与独特的基线生物标志物特征相关联。我们在一个大型德国慢性阻塞性肺病队列中探讨了与 18-54 个月死亡率相关的 18 个月疾病进展指标,包括过度充气参数和转移因子的变化:方法:分析德国观察性 COSYCONET 队列中 1364 名患者的数据,通过 Cox 危险回归模型评估疾病进展和改善模式对死亡率的影响。使用逻辑回归和随机森林模型评估了生物标志物和慢性阻塞性肺病评估测试项目与疾病进展或改善表型之间的关系:结果:18-54 个月死亡风险的增加与 KCO 预测百分比的下降(递增 7.5%)和 FEV1 的下降(递增 20 mL)、RV/TLC 的上升(递增 2%)和 SGRQ 的上升(≥6 分)以及 18 个月时恶化等级达到 2 级有关。KCO预测百分比下降≥7.5%和RV/TLC增加≥2%是衡量18个月疾病进展的最常见指标,分别出现在约52%和约46%的患者中。IL-6和CRP阈值与中长期疾病指标有显著关联:结论:在慢性阻塞性肺病多中心队列中,当前疾病活动的新标志物可预测中期死亡率,而基线生物标志物则无法预测中期死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respirology
Respirology 医学-呼吸系统
CiteScore
10.60
自引率
5.80%
发文量
225
审稿时长
1 months
期刊介绍: Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery. The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences. Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
期刊最新文献
Correction to APSR Annual Conference - 28th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong. Respirology 29 (Suppl. 3). COPD is associated with increased cardiovascular disease risk independent of phenotype. Letter from Indonesia. Effects of home-based telerehabilitation-assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trial. Lung cancer (internet-based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1